文献速递关节外科

结构化疼痛管理下翻修关节置换不增加阿片类药物需求

Revision Arthroplasty Does Not Require More Opioids Than Primaries: A Review of Prescribing Practices After Implementation of a Structured Perioperative Pain Management Strategy.
PubMed 文献 · J Arthroplasty · 2020-04-14

该回顾性队列研究纳入2014年1月至2018年7月共1273例翻修关节置换病例,评估结构化多学科疼痛方案实施前后阿片类药物处方趋势。结果显示住院处方减少24.1%、门诊利用减少62.4%,且第5年翻修与初次置换的门诊阿片处方无显著差异。

要点

  • 结构化疼痛方案使翻修关节置换住院阿片处方减少24.1%、门诊利用减少62.4%。
  • 全髋和全膝翻修亚组分别减少60.6%和64.0%。
  • 第5年翻修与初次置换的门诊阿片处方无显著差异。

核心结论

  • 结构化阿片减量策略使翻修关节置换患者阿片处方显著减少,且翻修患者门诊阿片需求不高于初次置换患者。

研究设计与样本

  • 回顾性队列研究(证据等级III),纳入2014年1月至2018年7月共1273例翻修关节置换病例,以第一年为基线比较。

主要发现

  • 住院阿片处方减少24.1%,门诊利用减少62.4%。
  • 全髋翻修亚组减少60.6%,全膝翻修亚组减少64.0%。
  • 翻修患者基线口服吗啡当量处方比初次置换多32.5%,但第5年门诊处方无显著差异。

关键数值与推荐

  • 2015年1月起实施多学科疼痛方案,普遍适用于所有髋膝关节置换患者(含翻修),无排除。

临床怎么用

  • 翻修关节置换可纳入与初次置换相同的结构化阿片减量策略,无需因翻修而放宽阿片处方。

局限性

  • 回顾性设计,证据等级III,单机构数据,可能存在未控制的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a growing body of literature on opioid mitigation strategies following total joint arthroplasty. However, these have almost exclusively been studied in populations undergoing primary procedures, with revision arthroplasty historically thought to be more resistant due to procedural variability and complexity. We report on opioid utilization for revision arthroplasty following implementation of a structured, standardized opioid reduction strategy. METHODS: Beginning January 2015, a comprehensive multidisciplinary pain protocol was developed and applied universally to all patients undergoing hip and knee arthroplasty, including revisions, without exclusion. We performed a retrospective review of opioid prescription trends for the revision arthroplasty subgroup between January 2014 and July 2018, with the first year serving as a baseline for comparison. Inpatient and outpatient opioid prescription data, inpatient satisfaction scores, and quality metrics were also reviewed. RESULTS: We identified 1273 revision arthroplasty cases in the study period. There was a significant reduction in average oral morphine equivalents utilized per procedure when comparing preintervention and postimplementation values. Overall, inpatient prescriptions decreased 24.1% and outpatient utilization decreased 62.4% over the study period. Significant reductions were seen in both the total hip (60.6%) and total knee (64.0%) subgroups. Although revision arthroplasty patients were prescribed 32.5% more oral morphine equivalents at baseline, at year 5 there was no significant difference in outpatient prescriptions between primary and revision subgroups. CONCLUSION: At our institution, a standardized opioid reduction strategy has resulted in marked reduction in opioid prescriptions for revision arthroplasty patients in line with generally successful reductions for primary arthroplasty. More importantly, with this approach, revision arthroplasty patients required no more outpatient opioids than their primary counterparts. LEVEL OF EVIDENCE: Level III, Retrospective cohort study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Deen JT, Stone WZ, Gray CF, et al. Revision Arthroplasty Does Not Require More Opioids Than Primaries: A Review of Prescribing Practices After Implementation of a Structured Perioperative Pain Management Strategy. J Arthroplasty. 2020. PMID: 32482474. doi:10.1016/j.arth.2020.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。